As is often the case with cancer treatments, many patients are able to benefit from therapy for a time. Tumor activity ...
Pfizer Inc. (NYSE: PFE) today announced positive topline progression-free (PFS) survival results from Cohort 3, a separate randomized cohort of the ...
NSCLC remains the leading cause of cancer-related mortality worldwide, with EGFR mutations being a critical driver in approximately 10-15% of lung adenocarcinomas in Western populations, and up to 40% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results